PE99699A1 - Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante - Google Patents
Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueanteInfo
- Publication number
- PE99699A1 PE99699A1 PE1998000612A PE00061298A PE99699A1 PE 99699 A1 PE99699 A1 PE 99699A1 PE 1998000612 A PE1998000612 A PE 1998000612A PE 00061298 A PE00061298 A PE 00061298A PE 99699 A1 PE99699 A1 PE 99699A1
- Authority
- PE
- Peru
- Prior art keywords
- selective inhibitor
- blocker
- composition including
- serotonin reabsorption
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9714675.7A GB9714675D0 (en) | 1997-07-11 | 1997-07-11 | Novel composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE99699A1 true PE99699A1 (es) | 1999-12-21 |
Family
ID=10815744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000612A PE99699A1 (es) | 1997-07-11 | 1998-07-10 | Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0996466A2 (fr) |
| JP (1) | JP2002508003A (fr) |
| KR (1) | KR20010021644A (fr) |
| CN (1) | CN1262627A (fr) |
| AP (1) | AP2000001728A0 (fr) |
| AR (1) | AR016128A1 (fr) |
| AU (1) | AU9340198A (fr) |
| BG (1) | BG104119A (fr) |
| BR (1) | BR9810996A (fr) |
| CA (1) | CA2295822A1 (fr) |
| CO (1) | CO4950552A1 (fr) |
| DZ (1) | DZ2556A1 (fr) |
| EA (1) | EA200000112A1 (fr) |
| GB (1) | GB9714675D0 (fr) |
| HU (1) | HUP0003074A3 (fr) |
| ID (1) | ID24191A (fr) |
| IL (1) | IL133869A0 (fr) |
| MA (1) | MA24604A1 (fr) |
| NO (1) | NO20000107L (fr) |
| OA (1) | OA11276A (fr) |
| PE (1) | PE99699A1 (fr) |
| PL (1) | PL338017A1 (fr) |
| SK (1) | SK72000A3 (fr) |
| TR (1) | TR200000074T2 (fr) |
| WO (1) | WO1999002142A2 (fr) |
| ZA (1) | ZA986138B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69942009D1 (de) | 1998-10-15 | 2010-03-25 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
| HU230454B1 (hu) | 1998-11-02 | 2016-07-28 | Alkermes Pharma Ireland Limited | Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| CN1407884B (zh) | 1999-10-29 | 2012-06-20 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| GB0004003D0 (en) * | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| WO2002036099A1 (fr) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Preparations d'hydrocodone a liberation lente |
| AU2005283829A1 (en) * | 2004-09-17 | 2006-03-23 | Neurocure Ltd | Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder |
| CN100469356C (zh) * | 2006-09-08 | 2009-03-18 | 山东益康药业有限公司 | 复方阿替洛尔缓释片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2732335C2 (de) * | 1976-07-27 | 1983-01-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten |
| CA2134038C (fr) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentialisation des effets de medicaments |
| EP0714663A3 (fr) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A |
| WO1997006792A1 (fr) * | 1995-08-16 | 1997-02-27 | Eli Lilly And Company | Potentialisation de la production de serotonine |
| EP0792649A1 (fr) * | 1996-02-29 | 1997-09-03 | Eli Lilly And Company | Traitement de l'insomnie |
-
1997
- 1997-07-11 GB GBGB9714675.7A patent/GB9714675D0/en active Pending
-
1998
- 1998-07-07 AP APAP/P/1999/001728A patent/AP2000001728A0/en unknown
- 1998-07-07 KR KR1020007000202A patent/KR20010021644A/ko not_active Application Discontinuation
- 1998-07-07 TR TR2000/00074T patent/TR200000074T2/xx unknown
- 1998-07-07 EA EA200000112A patent/EA200000112A1/ru unknown
- 1998-07-07 BR BR9810996-0A patent/BR9810996A/pt not_active Application Discontinuation
- 1998-07-07 IL IL13386998A patent/IL133869A0/xx unknown
- 1998-07-07 HU HU0003074A patent/HUP0003074A3/hu unknown
- 1998-07-07 ID IDW20000035A patent/ID24191A/id unknown
- 1998-07-07 CN CN98806975A patent/CN1262627A/zh active Pending
- 1998-07-07 SK SK7-2000A patent/SK72000A3/sk unknown
- 1998-07-07 WO PCT/EP1998/004971 patent/WO1999002142A2/fr not_active Application Discontinuation
- 1998-07-07 CA CA002295822A patent/CA2295822A1/fr not_active Abandoned
- 1998-07-07 EP EP98946294A patent/EP0996466A2/fr not_active Withdrawn
- 1998-07-07 JP JP50818599A patent/JP2002508003A/ja active Pending
- 1998-07-07 PL PL98338017A patent/PL338017A1/xx unknown
- 1998-07-07 AU AU93401/98A patent/AU9340198A/en not_active Abandoned
- 1998-07-08 DZ DZ980166A patent/DZ2556A1/fr active
- 1998-07-10 MA MA25165A patent/MA24604A1/fr unknown
- 1998-07-10 AR ARP980103371A patent/AR016128A1/es unknown
- 1998-07-10 CO CO98039260A patent/CO4950552A1/es unknown
- 1998-07-10 PE PE1998000612A patent/PE99699A1/es not_active Application Discontinuation
- 1998-07-10 ZA ZA9806138A patent/ZA986138B/xx unknown
-
2000
- 2000-01-10 NO NO20000107A patent/NO20000107L/no not_active Application Discontinuation
- 2000-01-11 OA OA1200000006A patent/OA11276A/en unknown
- 2000-02-01 BG BG104119A patent/BG104119A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL133869A0 (en) | 2001-04-30 |
| AR016128A1 (es) | 2001-06-20 |
| EP0996466A2 (fr) | 2000-05-03 |
| AU9340198A (en) | 1999-02-08 |
| AP2000001728A0 (en) | 2000-03-31 |
| CA2295822A1 (fr) | 1999-01-21 |
| NO20000107D0 (no) | 2000-01-10 |
| HUP0003074A3 (en) | 2001-12-28 |
| DZ2556A1 (fr) | 2003-02-15 |
| WO1999002142A3 (fr) | 1999-04-15 |
| BR9810996A (pt) | 2000-08-08 |
| MA24604A1 (fr) | 1999-04-01 |
| ID24191A (id) | 2000-07-13 |
| JP2002508003A (ja) | 2002-03-12 |
| TR200000074T2 (tr) | 2000-05-22 |
| CO4950552A1 (es) | 2000-09-01 |
| SK72000A3 (en) | 2000-12-11 |
| NO20000107L (no) | 2000-01-10 |
| BG104119A (en) | 2000-12-29 |
| PL338017A1 (en) | 2000-09-25 |
| CN1262627A (zh) | 2000-08-09 |
| GB9714675D0 (en) | 1997-09-17 |
| KR20010021644A (ko) | 2001-03-15 |
| ZA986138B (en) | 2000-01-10 |
| HUP0003074A2 (hu) | 2001-01-29 |
| WO1999002142A2 (fr) | 1999-01-21 |
| OA11276A (en) | 2003-07-31 |
| EA200000112A1 (ru) | 2000-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4900058A1 (es) | Terapia de combinacion para el tratamiento de psicosis | |
| PE99699A1 (es) | Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante | |
| ES2172744T3 (es) | Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina. | |
| BR0008958A (pt) | Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc | |
| AR031822A1 (es) | Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular. | |
| ZA200509542B (en) | Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
| ES2153410T3 (es) | Elemento aislante de pared, piso o fachada y sistema para renovacion de aire. | |
| NO20053088L (no) | Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon. | |
| ATE319464T1 (de) | Diätetische nahrungsergänzung zur unterstützung des zerebrovaskulären tonus | |
| MY152919A (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| Fujishiro et al. | Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine | |
| JP2008013542A5 (fr) | ||
| ATE505192T1 (de) | Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein | |
| AR033748A1 (es) | Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo | |
| IS6894A (is) | Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda | |
| CY1106800T1 (el) | Μεθοδοι και συνθεσεις δια χρησιμοποιησεως μεταβολιτων τepφεναδινης εν συνδυασμω μετ’ αναστολεων λευκοτριενιου | |
| De Witte | Encountering religion through Accra's urban soundscape | |
| Freudenmann et al. | The Neuropsychopharmacology and Toxicology of 3, 4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA) | |
| PA8571901A1 (es) | Nueva composicion farmaceutica | |
| Kanbayashi et al. | Effects of donepezil (Aricept) on the rapid eye movement sleep of normal subjects | |
| AR017884A1 (es) | Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion | |
| Nishio et al. | Role of the lipoxygenase pathway in phenylephrine-induced vascular smooth muscle cell proliferation and migration | |
| AR018376A1 (es) | Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento | |
| RS51669B (en) | NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE | |
| AR020740A1 (es) | Composicion y metodo para tratar enfermedades alergicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |